Possible reasons and treatment methods for worsening of condition after taking donepezil (Aricept)

Donepezil is an acetylcholinesterase inhibitor widely used in patients with Alzheimer's disease (AD) and other cognitive disorders. It increases the concentration of acetylcholine in the brain by inhibiting the breakdown of acetylcholine, thereby improving cognitive function and daily living abilities. However, some patients experience worsening of their condition after taking donepezil. Although this situation is rare, it deserves great attention in clinical practice. The following is a detailed analysis from four aspects: drug mechanism, individual differences, comorbid diseases, and medication management.

Donepezil may cause Side effects manifested as worsening of cognition or behavior. Although the drug is designed to enhance cholinergic nerve conduction, in a small number of patients, a hypercholinergic state may cause dizziness, anxiety, insomnia, nausea, and even transient cognitive confusion. Especially in elderly patients or those with underlying cardiovascular and cerebrovascular diseases, drug-induced decreases in blood pressure or slowing of heart rate may further affect cerebral blood supply, indirectly leading to aggravation of cognitive or behavioral symptoms. In addition, individuals have different tolerances to drugs, and symptoms may rebound or temporarily worsen if the dose is too high or the dose is suddenly adjusted.

Drug interactions with other concomitant medications may be an important cause of exacerbation. Donepezil is mainly metabolized by the liver CYP2D6 and CYP3A4. Drugs related to these pathways (such as antidepressants, antiarrhythmic drugs, antifungal drugs, etc.) may change the plasma concentration of donepezil, resulting in too strong or too weak drug effect. A drug concentration that is too high may aggravate side effects, such as nausea, vomiting, bradycardia, etc., while a drug concentration that is insufficient may not be effective, resulting in a false deterioration of cognitive or behavioral status.

Comorbid diseases or disease progression are also potential factors for worsening of symptoms after taking the drug. Alzheimer's disease itself is a progressive neurodegenerative disease that causes a natural decline in cognition and daily functioning as the disease progresses. If the patient develops infection (such as urinary tract infection, pneumonia), metabolic abnormality (such as hyponatremia, thyroid dysfunction) or increased mental stress while taking the drug, it may also lead to temporary deterioration of cognitive function, which may be mistaken for a donepezil drug reaction.

In terms of management, the first step is assessment of drug tolerance and dose adjustment. Consider adjusting the dose of donepezil from 10 mg or 5 u200bu200bmg to a lower dose and observe whether the symptoms are relieved. At the same time, make sure to take the medication regularly as directed by your doctor and avoid increasing or decreasing the dose on your own. Secondly, comorbid diseases and drug interactions should be investigated, concomitant medications should be adjusted if necessary, and metabolic or infectious factors that can affect cognition should be corrected. For patients with severe intolerance or persistent exacerbation, temporary discontinuation of the drug or replacement with other acetylcholinesterase inhibitors (such as rivastigmine, galantamine) may be considered for individualized treatment.

In addition, clinical management requires Closely monitor changes in symptoms and vital signs, including cognitive assessment, observation of activities of daily living, blood pressure, heart rate, and electrolyte levels. Family members’ participation in daily observation and recording is very important for judging changes in condition and drug response. By comprehensively assessing the cause and adjusting dosage or drug regimen, most patients can return to stability, maximizing the therapeutic benefit of the drug while reducing potential risks.

In summary, exacerbations after taking donepezil may be caused by drug side effects, inappropriate dosage, drug interactions, or comorbid diseases. Management strategies should include individualized dose adjustment, investigation of influencing factors, regular monitoring, and drug replacement when necessary. Under scientific management under the guidance of doctors, donepezil remains an effective tool for improving cognitive function in Alzheimer's disease.

Reference link:https://www.drugs.com